Research
An extensive research project was carried out by the WHO who found, CBD is not addictive or harmful to health and has a multitude of therapeutic properties.
The WHO Expert Committee on Drug Dependence says that: “The range of conditions for which CBD has been assessed is diverse, consistent with its neuroprotective, antiepileptic, hypoxia-ischemia, anxiolytic, antipsychotic, analgesic, anti-inflammatory, anti-asthmatic, and antitumor properties….”
Furthermore, the United Nations research does not consider this CBD a drug since it does not create a high.
“In humans, CBD exhibits no effects indicative of any abuse or dependence potential…. To date, there is no evidence of public health-related problems associated with the use of pure CBD.”
There are many questions that people who have never used CBD often ask us. Here we detail several that the WHO Expert Committee has summarised in its report on the analysis of CBD:
WHO indicates that CBD is NOT addictive or harmful to health:
The study shows that according to studies carried out in animals, no tolerance has been identified nor have studies been reported that indicate physical dependence. In fact, the opposite effect has been identified. No adverse effect has been found for the abusive use of CBD so it does not produce any negative consequences for abuse.
From medical studies with humans, it is found that CBD has the same addiction properties as a placebo. Also, that cannabidiol does not produce, by itself, any significant psychoactive or cardiovascular effects.
Does not cause social alarm:
The WHO also acknowledges that no public concerns have been identified about the use of CBD or accidents related to this substance.
WHO notes that CBD has potential as a medicinal substance.
The report points to several advanced research programs that have shown its effectiveness against epilepsy and includes a list of other ailments for which CBD could be useful.
Overview table of diseases for which CBD
may have therapeutic benefits, taken from the WHO report:
| DISEASE | EFFECTS |
| Alzheimer’s disease | Antinflammatory,antiapoptotic in in vitro and in vivo models of Aβ-evoked neuroinflammatory and neurodegenerative responses. |
| Parkinson’s disease | Attenuation of the dopaminergic impairment in vivo; neurodegenerative; impairment of psychiatric rating and reduction of agitation, nightmare and aggressive behaviour in patients. |
| Multiple sclerosis | Improved signs of EAE in mice, antinflammatory and immunomodulatory properties. |
| Huntington’s disease | Neuroprotective and antioxidant in mice transgenic models;no significant clinically important differences in patients. |
| Hypoxia-ischemia injury | sort term neuroprotective effects;inhibition of excitotoxicity, oxidative stress and inflammation in vitro and in rodent models. |
| Pain | Analgesic effect in patients with neuropathic pain resistant to other treatments. |
| Psychosis | Attenuation of the behavioural and glial changes in animal models of schizophrenia;anti-psychotic properties on ketamine-induced symptoms |
| Anxiety | Reduction of muscular tension, restlessness, fatigue, problems in concentration,improvement of social interations in rodent models of enxiety and stress;reduced social anxiety in patients. |
| Depression | Anti-depressant effect in genetic rodent model of depression. |
| Cancer | Antiproliferative and anti-invasive actions in a large range of cancer types;induction of autophagy-mediated cancer cell death; chemopreventive effects. |
| Nausea | Suppression of nausea and conditioned gaoing in rats |
| inflammatory diseases | Antufammatory properties in several in vitro and in vivo models; inhibition of inflammatory cytokines and patways. |
| Rheumatoid arthritis | Inhibition of TNF-α in an animal model |
| infection | Acitivity against methicillin-resistant Staphylococcus aureus |
| Inflammatory bowl and Crohn’s diseases | Inhibition of macrophage recruitment and TNF-α secretion in vivo and ex vivo; reduction in disease activity index in Crohn’s patients |
| Cardiovascular diseases | Reduced infarct size through anti-oxidant and anti-inflammatory properties in vitro and in vivo. |
| Diabetic Complications | Attenuation of fibrosis and myocardial dysfunction |
SUBSTANCE IMPACT
The WHO research concluded that CBD lacks psychoactive properties, does not cause addiction, and also has promising therapeutic uses.
In addition, the WHO notes that they have not found adverse reactions and as such very few side effects when mixed with some medications. Provided in the references is a link to the website PROJECT CBD (https://www.projectcbd.org/) which is full of useful literature on CBD and its uses.
CBD EXPANSION
In North, America CBD is legal in all states, in the European zone, in Switzerland and the United Kingdom, but the CBD wave is going global, and it will continue to expand until it is a product most of us use daily.
HOW IS CBD USED OR ADMINISTERED?
Research has shown consumption of CBD should be something individualized for each person and a specific case. Each person is different and that is why were commended that every one starts with a small dose and increase as needed. In most cases, it is better for the person to consume small doses during the day than a single dose of greater quantity or concentration.
Orally, the effect of CBD (like our sublingual spray) usually takes between 30 and 90 minutes, whereas topically (such as our balm) has localized action and can be beneficial for the treatment of inflammatory diseases such as dermatitis, eczema, psoriasis and acne. Vaping is the fastest way to get CBD into your system, but it’s not for everyone, as we understand a lot of people do not like to smoke – a point to note is that our e-liquids contain no nicotine.